CDK1 and neoplasm: In the present study, the cdk1-cyclin B- and the cdk2-cyclin A-complex were reduced in parental cells treated with temsirolimus, whereas a strong up-regulation was seen in drug resistant tumor cells, particularly when re-treated with temsirolimus.